Sagimet Biosciences price target lowered to $25 from $27 at Guggenheim

Guggenheim lowered the firm’s price target on Sagimet Biosciences (SGMT) to $25 from $27 and keeps a Buy rating on the shares. The firm is “enthusiastically supportive” of Sagimet’s strategic pivot to focus on development of acne, including advancement of denifanstat to Phase 3 in the second half of 26, the analyst tells investors.